Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Rotavirus Vaccines

로타바이러스 백신

  • Koh, Hong (Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital)
  • 고홍 (연세대학교 의과대학 소아과학교실, 세브란스 어린이병원)
  • Received : 2009.10.31
  • Accepted : 2009.11.06
  • Published : 20091100
Download PDF
⟨ Previous Next ⟩

Abstract

Rotavirus infection is the leading cause of severe diarrhea disease in infants and young children worldwide. Rotavirus infects every child at least once by her/his $5^{th}$ birthday. It has been known that single episode of rotavirus infection can protect or alleviate subsequent illness caused by both homotypic and heterotypic rotaviruses. There are two currently licensed rotavirus vaccines. One is human-bovine rotavirus reassortant pentavalent vaccine ($RotaTeq^{TM}$), which contains five reassortant rotavirus (expressing protein G1, G2, G3, G4 and P[8]) and was licensed in Korea for use among infants in 2007. Another is live-attenuated human rotavirus vaccine ($Rotarix^{TM}$) derived from 89-12 strain which represents the most common of the human rotavirus VP7(G1) and VP4(P[8]) antigens. $Rotarix^{TM}$ was licensed in Korea in 2008. Both live oral rotavirus vaccines are efficacious in preventing severe rotavirus gastroenteritis.

Keywords

References

  1. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severer childhood diarrhea. Emerg Infect Dis 2006; 12:304-6. https://doi.org/10.3201/eid1202.050006
  2. Parashar UD, Hummelman EG, Bresee JS, miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg infect Dis 2003;9:565-72. https://doi.org/10.3201/eid0905.020562
  3. Dennehy PH. Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J 2000;19(10 Suppl):103S-5S. https://doi.org/10.1097/00006454-200010001-00003
  4. Glass RI, Bresee J, Jiang B, Parashar U, Yee E, Gentsch J. Rotavirus and rotavirus vaccines. Adv Exp Med Biol 2006;582:42-54.
  5. Dennehy PH. Rotavirus vaccines: an overview. Clin Microbial Rev 2008;21:198-208. https://doi.org/10.1128/CMR.00029-07
  6. World Health Organization. Rotavirus vaccines: WHO position Paper. Wkly Epidemiol Rec 1999;74:33-40.
  7. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. https://doi.org/10.1056/NEJMoa052434
  8. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriquez A, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. https://doi.org/10.1056/NEJMoa052664
  9. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973;2:1281-3.
  10. Kalica AR, Greenberg HB, Wyatt RG, Flores J, Sereno MM, Kapikian AZ, et al. Genes of human (strain Wa) and bovine (strain UK) rotaviruses that code for neutralization and subgroup antigens. Wirology 1981;112:385-90.
  11. Ball JM, Tian P, Zeng CQ, Morris AP, Estes MK. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 1996;272:101-4. https://doi.org/10.1126/science.272.5258.101
  12. Hoshino Y, Kapikian AZ. Rotavirus vaccine development for the preventioin of severe diarrhea in infants and young children. Trends Microbiol 1994;2:242-9. https://doi.org/10.1016/0966-842X(94)90629-7
  13. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infct Dis 2005;192 Suppl 1:146-59. https://doi.org/10.1086/431499
  14. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005;15:29-56. https://doi.org/10.1002/rmv.448
  15. Kim JS, Kang JO, Cho SC, Jang YT, Min SA, Park TH, et al. Epidemiological profile of rotavirus infection in the Republic of Korea: results from prospective surveillance in the Jeongeub district, 1 July 2002 through 30 June 2004. J Infect Dis 2005;192:S49-56. https://doi.org/10.1086/431506
  16. Kang JH. Epidemiological profile of rotavirus infection in Korea. 24th Annual meeting of the European Society for Pediatric Infectious Disease. 2006 May 3-5;Basel Switzerland.
  17. 질병관리본부. 주간 건강과 질병. 2008;1:325-8.
  18. Kim DS, Lee TJ, Kang JH, Kim JH, Lee JH, Ma SH, et al. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in health infants in Korea. Pediatr Infect Dis J 2008;27: 177-8.
  19. Block SL, Vesikari T, Goveia MG, Rivers SM, Adeyi BA, Dallas MJ, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007;119:11-8. https://doi.org/10.1542/peds.2006-2058
  20. American Academy of Pediatrics Committee on Infectious Disease. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 2007;119:171-82. https://doi.org/10.1542/peds.2006-3134
  21. Bernstein KI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomized placebo-controlled trial. Lancet 1999;354:287-90. https://doi.org/10.1016/S0140-6736(98)12106-2
  22. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet 2007;370:1757-63. https://doi.org/10.1016/S0140-6736(07)61744-9
  23. 대한소아과학회. 예방접종지침서. 광문출판사 2008;6:231-47.